Abstract: The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt, ester, hydrate, derivative, prodrug or metabolite thereof for use in the prevention or treatment of an infection by a virus in an individual.

Abstract: Pharmaceutical composition and their uses are disclosed, the composition comprising at least one methyl cyclodextrin having a molar substitution (MS) degree of between 0.05 and 1.5 in the treatment and/or prevention of diseases that can be treated and/or prevented by an increase in the HDL cholesterol level.

Abstract: Pharmaceutical composition and their uses are disclosed, the composition comprising at least one methyl cyclodextrin having a molar substitution (MS) degree of between 0.05 and 1.5 in the treatment and/or prevention of diseases that can be treated and/or prevented by an increase in the HDL cholesterol level.

Abstract: The invention relates to a novel use of a pharmaceutical composition comprising at least one methyl cyclodextrin having a molar substitution (MS) degree of between 0.05 and 1.5 in the treatment and/or prevention of diseases that can be treated and/or prevented by an increase in the HDL cholesterol level. The invention also relates to the use thereof in the treatment and/or prevention of atherosclerosis or complications relating to an atheroma, and/or diseases of the central nervous system. The pharmaceutical compositions of the invention can also be used to stimulate the reduction of circulating fatty acid and triglyceride levels and to reduce or prevent atheromatous plaques.

Abstract: The invention relates to a novel use of a pharmaceutical composition comprising at least one methyl cyclodextrin having a molar substitution (MS) degree of between 0.05 and 1.5 in the treatment and/or prevention of diseases that can be treated and/or prevented by an increase in the HDL cholesterol level. The invention also relates to the use thereof in the treatment and/or prevention of atherosclerosis or complications relating to an atheroma, and/or diseases of the central nervous system. The pharmaceutical compositions of the invention can also be used to stimulate the reduction of circulating fatty acid and triglyceride levels and to reduce or prevent atheromatous plaques.

Abstract: The invention relates to a method for the extraction of recombinant periplasmic proteins wherein arginine is used as the extraction agent. In particular, the invention relates to a method for the extraction of a periplasmic protein of interest, which essentially consists in:(i) suspending the pellet of cells or of cell debris from cells, which cells originate from the culture of a prokaryotic microorganism transformed with an expression vector containing a gene coding for the said protein and means for its expression in the periplasm of the said microorganism, in a buffer solution containing arginine; and(ii) recovering the protein of interest in the supernatant of the bacterial suspension thereby obtained.

Abstract: The invention relates to a method for the extraction of recombinant periplasmic proteins wherein arginine is used as the extraction agent. In particular, the invention relates to a method for the extraction of a periplasmic protein of interest, which essentially consists in:(i) suspending the pellet of cells or of cell debris from cells, which cells originate from the culture of a prokaryotic microorganism transformed with an expression vector containing a gene coding for the protein and means for its expression in the periplasm of the microorganism, in a buffer solution containing arginine; and(ii) recovering the protein of interest in the supernatant of the bacterial suspension thereby obtained.

Abstract: The invention concerns a new urate oxidase activity protein which has the following sequence (SEQ ID NO:1): ##STR1## optionally preceded by a methionine, or in that it may present a degree of substantial homology with this sequence.The invention is also aimed at medicines containing this protein as well as the genetic engineering implements to obtain it.

Abstract: The present invention relates toa mutant strain of Xanthomonas campestris;a method of preparing xanthan by fermentation of said strain; anda non-viscous xanthan capable of being obtained by said method.

Abstract: The present invention relates toa mutant strain of Xanthomonas campestris;a method of preparing xanthan by fermentation of said strain; anda non-viscous xanthan capable of being obtained by said method.

Abstract: The invention concerns a new urate oxidase activity protein which has the following sequence:______________________________________ Ser Ala Val Lys Ala Ala Arg Tyr Gly Lys Asp Asn Val Arg Val Tyr Lys Val His Lys Asp Glu Lys Thr Gly Val Gln Thr Val Tyr Glu Met Thr Val Cys Val Leu Leu Glu Gly Glu Ile Glu Thr Ser Tyr Thr Lys Ala Asp Asn Ser Val Ile Val Ala Thr Asp Ser Ile Lys Asn Thr Ile Tyr Ile Thr Ala Lys Gln Asn Pro Val Thr Pro Pro Glu Leu Phe Gly Ser Ile Leu Gly Thr His Phe Ile Glu Lys Tyr Asn His Ile His Ala Ala His Val Asn Ile Val Cys His Arg Trp Thr Arg Met Asp Ile Asp Gly Lys Pro His Pro His Ser Phe Ile Arg Asp Ser Glu Glu Lys Arg Asn Val Gln Val Asp Val Val Glu Gly Lys Gly Ile Asp Ile Lys Ser Ser Leu Ser Gly Leu Thr Val Leu Lys Ser Thr Asn Ser Gln Phe Trp Gly Phe Leu Arg Asp Glu Tyr Thr Thr Leu Lys Glu Thr Trp Asp Arg Ile Leu Ser Thr Asp Val Asp Ala Thr Trp Gln Trp Lys Asn Phe Ser Gly Leu Gln Glu Val Arg Ser His Val Pro Lys Phe Asp Ala Thr Trp Ala Thr Ala Arg Glu Val Thr Leu Lys Thr Phe Ala Glu Asp Asn